State Farm Mutual Automobile Insurance Co Rotates From Cyclicals Into Defensives and Tech Plumbing

There are no classic “biggest buys” this quarter; conviction is rising not through new additions but by what State Farm refuses to touch. The clearest decision is to keep massive, unchanged stakes in durable, oligopolistic platforms across healthcare, tech, and consumer staples.

• Johnson & Johnson at 6.09% is untouched, despite a very large embedded gain versus cost; they’re content to let this be the ballast for the healthcare book.
• Illinois Tool Works at 4.31% remains fully intact, signaling confidence in industrial margins even as more cyclical peers are harvested.
• Microsoft, Alphabet, and Meta — all left unchanged — show a deliberate choice to stay long the broad software and advertising rails of AI rather than chase incremental upside elsewhere.
• Exxon and Chevron, both steady at 4.08% and 2.17%, highlight a view that integrated oil cash flows remain attractive in a higher-for-longer energy backdrop.
• Procter & Gamble, Coca‑Cola, Pepsi, ADM, and McCormick are all untouched, reflecting a quiet but clear conviction that consumer staples’ pricing power and volume stability still deserve a meaningful sleeve.

This is a portfolio that believes its core franchises are correctly sized already; conviction is rising by not over‑trading the best balance sheets and widest moats.

The real story sits in the sell tape: State Farm spent the quarter taking real money off the table where the gains are most extreme or the stories most fully priced.

• Caterpillar was cut by 16.4%, freeing up about $2.03B of exposure even as it remains the single largest position at 8.13%; after a gain of more than 950% versus their average cost, this is classic risk management in a late‑cycle industrial.
• Eli Lilly was reduced by 13.8%, pulling roughly $1.58B off the table, but leaving a huge 7.80% weight — they’re acknowledging how far the obesity/GLP‑1 narrative has run without giving up on it.
• Disney absorbed the most brutal trim in percentage terms at -33.4%, with an estimated $731.7M sliced out; the cut suggests increasing skepticism around legacy media economics and capital intensity versus the rest of the consumer book.
• Corning, KLA, Deere, Nucor, Apple, and modest cuts to Intel, GE, Vulcan, and Wells Fargo look like incremental profit‑taking across cyclicals, capital goods, and semis after multi‑hundred‑percent gains.

What’s striking is where they didn’t trim: the core pharma complex (outside LLY), integrated oils, and staple‑heavy consumer exposure were largely left intact. The trims read like classic funding trades out of the most pro‑cyclical and most re‑rated winners.

The sector chart shows a subtle but telling rotation. Industrials and healthcare both ticked down — industrials to 24.45% from 25.30%, healthcare to 23.38% from 23.81% — almost entirely driven by the Caterpillar and Lilly trims.

On the other side, technology crept up to 21.20% from 20.46% without net new tech buys, purely because State Farm chose not to sell its big software and semiconductor infrastructure bets while harvesting elsewhere. Energy edged up to 6.75% from 6.50%, consumer staples to 5.88% from 5.66%, and financials to 4.52% from 4.36%, underscoring a tilt toward cash‑rich, dividend‑paying sectors.

Consumer discretionary nudged down to 8.84% from 9.11% on the Disney reduction, even as Walmart, Procter & Gamble, GATX, and ADT stayed put — effectively concentrating the sleeve in higher‑quality and more contracted revenue streams. Basic materials and telecom exposures were kept steady to slightly higher, reflecting comfort with diversified commodity and connectivity infrastructure rather than pure growth stories.

Under the hood, the rotation says they want less beta to capex-heavy cyclicals and more exposure to tech-and-staples balance sheets that can weather a slower macro tape.

Taken together, the quarter paints a clear picture: State Farm is acting like a long‑duration insurer finally content with the equity gains of this run, pruning cyclicals and momentum darlings and entrenching around high‑quality, cash‑generating platforms that can carry the book through a bumpier macro regime.

Expect more of the same behavior if volatility picks up: incremental trims in names that have run farthest from their cost basis, especially capital‑intensive industrials and richly valued growth, with the proceeds recycled into staples, integrated energy, and the software and semiconductor plumbing that underpins AI and digitization. The complete absence of new top‑50 positions hints that idea generation isn’t the constraint; valuation discipline is.

The lingering overweight in industrials and healthcare, despite small cuts, suggests they still see real‑asset exposure and pharma pipelines as core to the portfolio’s long‑term earnings power. But the directional moves — slightly lower cyclicals, slightly higher tech and defensives — imply that from here, State Farm would rather be paid in durable free cash flow than in one more turn of operating leverage. For outside observers, this looks less like a market call and more like a deliberate de‑risking of equity beta inside a very large insurance balance sheet.